Search

Your search keyword '"Jones WD"' showing total 232 results

Search Constraints

Start Over You searched for: Author "Jones WD" Remove constraint Author: "Jones WD"
232 results on '"Jones WD"'

Search Results

151. A simple method for coupling aldehydes to solid support.

152. Evidence for nitric oxide regulation of hamster sperm hyperactivation.

153. Synthesis and Characterization of (Tris(3,5-dimethylpyrazolyl)borato)rhodium Alkyl and Vinyl Chloride Complexes.

154. Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 5'-monophosphate dehydrogenase inhibitor analogue of selenazofurin.

156. Signal processing and calibration of continuous-wave focused CO(2) Doppler lidars for atmospheric backscatter measurement.

157. Viruses, neurosis and fatigue.

158. The effect of social adversity on the fatigue syndrome, psychiatric disorders and physical recovery, following glandular fever.

159. Tuberculosis in a correctional facility.

160. Patient classification.

161. Inhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032.

162. Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids.

163. Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C.

164. Suppression of interleukin-1 beta and LDL scavenger receptor expression in macrophages by a selective protein kinase C inhibitor.

165. Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid.

166. MDL 27,032 relaxes vascular smooth muscle and inhibits protein kinase C.

167. MDL 27,032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone], an active site-directed inhibitor of protein kinase C and cyclic AMP-dependent protein kinase that relaxes vascular smooth muscle.

168. Geographic distribution of phage types among cultures of Mycobacterium tuberculosis. II. Cultures from India and South Africa.

169. Phage-type patterns of Mycobacterium tuberculosis from Southeast Asian immigrants.

170. Recurrent facial fibrous histiocytoma.

171. Mental health patients in primary health care services in Nepal.

172. Bacteriophage typing of Mycobacterium tuberculosis cultures from incidents of suspected laboratory cross-contamination.

173. Use of phage F-phi WJ-1 of Mycobacterium fortuitum to discern more phage types of Mycobacterium tuberculosis.

174. Applications of reconstructive craniofacial techniques to acute craniofacial trauma.

175. Typing Mycobacterium tuberculosis with mycobacteriophage Bo4.

178. Host modification and restriction with a mycobacteriophage isolated from a pseudolysogenic Mycobacterium chelonei.

179. Bacteriophage types of Mycobacterium tuberculosis in the United States.

181. Expression of proteins of Mycobacterium tuberculosis in Escherichia coli and potential of recombinant genes and proteins for development of diagnostic reagents.

182. Further studies of mycobacteriophage 33D (Warsaw) for differentiation of BCG from M. bovis and M. tubeculosis.

183. Modification of methods used in bacteriophage typing of Mycobacterium tuberculosis isolates.

184. Australian aerosol backscatter survey.

185. Restriction fragment analysis of chromosomal DNA defines different strains of Mycobacterium tuberculosis.

186. False-positive cultures of Mycobacterium tuberculosis.

188. The case for the inferiorly based posterior pharyngeal flap.

189. Hazel elephant redux.

191. Antiallergic agents. Xanthone-2,7-dicarboxylic acid derivatives.

192. Tuberculosis epidemic among hospital personnel.

193. The usefulness of phage typing Mycobacterium tuberculosis isolates.

194. Hospital engineering is technology management.

198. Differentiation of known strains of BCG from isolates of mycobacterium bovis and Mycobacterium tuberculosis by using mycobacteriophage 33D.

Catalog

Books, media, physical & digital resources